<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02518022</url>
  </required_header>
  <id_info>
    <org_study_id>BEER2015</org_study_id>
    <nct_id>NCT02518022</nct_id>
  </id_info>
  <brief_title>How to be Safe With Alcoholic Drinks in Diabetes</brief_title>
  <acronym>BEER</acronym>
  <official_title>A Monocentric, Controlled, Randomized, Open-label Cross-over Study to Explore the Possible Insulin Treatment of Beverages Containing Alcohol and Carbohydrates in Adolescents and Young Adults With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kinderkrankenhaus auf der Bult</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kinderkrankenhaus auf der Bult</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show that during and after drinking beer a treatment strategy
      by insulin bolus and reduction of basal rate reduces the rate of hyperglycaemia without an
      increase of hypoglycaemic events compared to a treatment strategy according to the standard
      recommendation without insulin Bolus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will get two times a height, weight an gender based amount of beer.

      One time (Standard) there will be no Insulin given for the beer. Second time (Intervention)
      half of the carbohydrates containing in the beer will be covered with Insulin, additionally
      the basal rate will be set to 50% for 12 hours.

      All the time, Glucose will be monitored by continuous subcutaneous Glucose Monitoring.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    unexpected low willingness of patient to participate on the study
  </why_stopped>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Number of hypoglycaemic events &lt;70 mg/dl per arm from begin of consumption until lunch next day (12:00 am)</measure>
    <time_frame>18 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Area under the curve Glucose Sensor &gt;120 mg/dl from begin of drinking to lunch next day</measure>
    <time_frame>18 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Total Area under the curve</measure>
    <time_frame>18 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• average Sensor Glucose from begin of drinking to 12 hours past and to lunch next day</measure>
    <time_frame>18 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Time from end of consumption to nadir of serum glucose</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Number of hypoglycaemic events &lt;70 mg/dl per treatment arm until lunch</measure>
    <time_frame>18 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Number of hyperglycaemic events &gt; 180 mg/dl per treatment arm until lunch</measure>
    <time_frame>18 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Time in Hypoglycaemia &lt;70 mg/dl per treatment arm</measure>
    <time_frame>18 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Max. alcohol in expiratory breath</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For carbohydrates in beer, subjects will get covering by Insulin (1/2 of calculated amount). As well Insulin basal rate will set to half for 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Insulin Treatment of carbohydrates in beer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin for beer</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Novorapid or Humalog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent by participants

          -  Signed informed consent by parent or legal guardian of adolescent participants &lt;18
             years of age

          -  Age between16-21 years (both including)

          -  &gt;1 year Type 1 Diabetes

          -  continuous subcutaneous insulin infusion for at least 3 months

          -  HbA1c 7-10 % (both including)

          -  BMI between10-95th percentile for gender and age (both including) for adolescents,
             &lt;95th percentile for adults

          -  Ability to wear glucose sensor

          -  Normal liver enzymes (alanine aminotransferase , aspartate transaminase ,
             Gamma-Glutamyl-Transferase, bilirubin) in age appropriate range by local lab

        Exclusion Criteria:

          -  Severe hypoglycaemia or diabetic ketoacidosis in the past 6 month

          -  Alcohol or drug abuse

          -  Psychiatric disorder

          -  Unstable other metabolic disease as judged by investigator

          -  Intake of glucocorticoids or growth hormone

          -  Allergy to adhesive

          -  Coeliac disease

          -  Women of child-bearing potential who have a positive pregnancy test at screening or
             plan to become pregnant during the course of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torben Biester, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Physician</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kinder - und Jugendkrankenhaus AUF DER BULT</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Krebs HA, Freedland RA, Hems R, Stubbs M. Inhibition of hepatic gluconeogenesis by ethanol. Biochem J. 1969 Mar;112(1):117-24.</citation>
    <PMID>5774487</PMID>
  </reference>
  <reference>
    <citation>Turner BC, Jenkins E, Kerr D, Sherwin RS, Cavan DA. The effect of evening alcohol consumption on next-morning glucose control in type 1 diabetes. Diabetes Care. 2001 Nov;24(11):1888-93.</citation>
    <PMID>11679452</PMID>
  </reference>
  <reference>
    <citation>Gin H, Morlat P, Ragnaud JM, Aubertin J. Short-term effect of red wine (consumed during meals) on insulin requirement and glucose tolerance in diabetic patients. Diabetes Care. 1992 Apr;15(4):546-8.</citation>
    <PMID>1499475</PMID>
  </reference>
  <reference>
    <citation>Jennifer F. Scheel, Karin Schielke, Stefan Lautenbacher, Sabine Aust1, Simone Kremer, Jörg Wolstein; Low-Dose Alcohol Effects on Attention in Adolescents, Zeitschrift für Neuropsychologie, 24 (2), 2013, 103 - 111</citation>
  </reference>
  <reference>
    <citation>Koivisto VA, Tulokas S, Toivonen M, Haapa E, Pelkonen R. Alcohol with a meal has no adverse effects on postprandial glucose homeostasis in diabetic patients. Diabetes Care. 1993 Dec;16(12):1612-4.</citation>
    <PMID>8299457</PMID>
  </reference>
  <reference>
    <citation>Seidl S, Jensen U, Alt A. The calculation of blood ethanol concentrations in males and females. Int J Legal Med. 2000;114(1-2):71-7.</citation>
    <PMID>11197633</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2015</study_first_submitted>
  <study_first_submitted_qc>August 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2015</study_first_posted>
  <last_update_submitted>August 3, 2016</last_update_submitted>
  <last_update_submitted_qc>August 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 Diabetes mellitus</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>continuous subcutaneous insulin infusion</keyword>
  <keyword>Alcohol</keyword>
  <keyword>continuous glucose monitoring system</keyword>
  <keyword>Nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

